Aveanna Healthcare (AVAH)
(Delayed Data from NSDQ)
$2.49 USD
-0.08 (-3.11%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $2.50 +0.01 (0.40%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
AVAH 2.49 -0.08(-3.11%)
Will AVAH be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for AVAH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AVAH
Compared to Estimates, Aveanna (AVAH) Q1 Earnings: A Look at Key Metrics
Aveanna Healthcare (AVAH) Reports Q1 Loss, Tops Revenue Estimates
AVAH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Countdown to Aveanna (AVAH) Q1 Earnings: Wall Street Forecasts for Key Metrics
Addus HomeCare (ADUS) Q1 Earnings and Revenues Beat Estimates
Aveanna (AVAH) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Other News for AVAH
Aveanna Healthcare Enhances Investor Communication with Presentation
Aveanna to Participate at the UBS Healthcare Services Cape Cod Summit and Jefferies Global Healthcare Conference
Truist Financial Sticks to Their Hold Rating for Aveanna Healthcare Holdings (AVAH)
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Oncolytics Biotech (ONCY), Aveanna Healthcare Holdings (AVAH) and Sanofi (OtherSNYNF)
Polen Capital Q1 2024 Credit Opportunities Full Discretion Composite Commentary